Last reviewed · How we verify
NCT05024331
A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor
trial in Pediatric Solid Tumor in 10 participants. Completed in 12 August 2021.
30 July 2021
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 30 July 2021 |
| Primary completion | 30 July 2021 |
| Estimated completion | 12 August 2021 |
| Sites | 1 location across South Korea |
Conditions studied
- Pediatric Solid Tumor — all drugs for Pediatric Solid Tumor →
Sponsor
Samsung Medical Center
Who can join
19 and older, any sex, with Pediatric Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to compare and evaluate the predicted values of the participants, and the algorithm predicted values of ANC level reduction periods after high-capacity chemotherapy in pediatric solid tumor patients. The participants are pediatricians who voluntarily participate in this study and consent to this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05024331
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pediatric Solid Tumor
Currently open trials in the same condition.
- NCT05521984 — Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SG · Phase 1 · recruiting
- NCT05620862 — Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Rela · Phase 1 · active not recruiting
- NCT04897321 — B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) · Phase 1 · recruiting
- NCT05151718 — Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents · recruiting
- NCT04222413 — Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors · Phase 1 · recruiting
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05024331 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 13 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05024331.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing